2m 2m 2m 2m 2m 2m 2m
Bioline RX Sp ADR (BLRX)
NASDAQ
$3.29-$0.10 (-3.10%)
Price as of Jun 03, 2026 4:10 PM EDT- $16.4MMarket Cap
- -19.67%1-Year Change
- BiotechnologyIndustry
Bioline RX Sp ADR (BLRX)
$3.29-$0.10 (-3.10%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 1.2M -95.92% | 28.9M +502.92% | 4.8M N/A | N/A N/A | |
Cost of Revenue | 230,000 -97.52% | 9.3M +150.89% | 3.7M N/A | N/A N/A | |
Gross Profit | 950,000 -95.17% | 19.7M +1,675.90% | 1.1M N/A | 0 N/A | |
Sales and Marketing Expense | 3.1M -50.26% | 6.3M +0.17% | 6.3M +24.56% | 5.1M +17.60% | |
Research and Development Expense | -8.1M -11.54% | -9.1M -26.92% | -12.5M -28.99% | -17.6M -9.44% | |
Depreciation and Amortization Expense | 523,000 -87.13% | 4.1M +193.71% | 1.4M +111.62% | 654,000 -6.97% | |
Total Operating Expenses | 3.1M -50.26% | 6.3M +0.17% | 6.3M +24.56% | 5.1M +17.60% | |
Operating Profit | -10.3M -49.59% | -20.4M -58.93% | -49.7M +70.44% | -29.2M +17.68% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -1.3M -86.21% | -9.1M +323.23% | -2.1M +20.04% | -1.8M N/A | |
Interest Income and Expense and Net | -1.3M -86.21% | -9.1M +323.23% | -2.1M +20.04% | -1.8M N/A | |
Total Nonoperating Income and Expense | 1.3M -86.21% | 9.1M +323.23% | 2.1M +20.04% | 1.8M N/A | |
Income before Taxes | -2.0M -78.03% | -9.2M -84.79% | -60.6M +142.93% | -25.0M -7.77% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -2.0M -78.03% | -9.2M -84.79% | -60.6M +142.93% | -25.0M -7.77% | |
Net Income from Continuing Operations Applicable to Common | -2.0M -78.03% | -9.2M -84.79% | -60.6M +142.93% | -25.0M -7.77% | |
Basic EPS and Net Income | 0.00 +100.00% | -0.01 -83.33% | -0.06 +100.00% | -0.03 N/A | |
Diluted EPS and Net Income | 0.00 +100.00% | -0.01 -83.33% | -0.06 +100.00% | -0.03 N/A | |
Basic Weighted Average Shares | 2.5B +105.76% | 1.2B +24.37% | 963.4M +24.47% | 774.0M +16.75% | |
Diluted Weighted Average Shares | 2.5B +105.76% | 1.2B +24.37% | 963.4M +24.47% | 774.0M +16.75% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 3.3M -68.86% | 10.4M +145.26% | 4.3M -59.81% | 10.6M -18.50% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 3.3M -68.86% | 10.4M +145.26% | 4.3M -59.81% | 10.6M -18.50% | |
Total Current Assets | 23.7M -12.63% | 27.1M -42.56% | 47.2M -9.27% | 52.0M -9.41% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 160,000 -58.55% | 386,000 -18.39% | 473,000 -34.85% | 726,000 -23.74% | |
Total Long-Term Assets | 17.2M +45.94% | 11.8M -29.51% | 16.7M -31.34% | 24.4M +1.65% | |
Total Assets | 40.9M +5.14% | 38.9M -39.14% | 63.9M -16.31% | 76.4M -6.15% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 12.1M -21.31% | 15.4M -50.06% | 30.9M +188.90% | 10.7M +9.88% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 5.4M -45.84% | 10.0M -49.43% | 19.9M +33.54% | 14.9M +314.62% | |
Total Liabilities | 17.6M -30.99% | 25.4M -49.81% | 50.7M +98.50% | 25.5M +91.99% | |
Retained Earnings | -401.0M +0.29% | -399.8M +2.36% | -390.6M +18.37% | -330.0M +8.18% | |
Total Stockholders Equity | 23.3M +73.43% | 13.5M +1.80% | 13.2M -73.99% | 50.8M -25.33% | |
Total Shares Outstanding | 2.6B N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash Flow | |||||
Cash from Operating Activities | -8.1M -81.60% | -43.9M +94.06% | -22.6M -13.84% | -26.2M +11.31% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -8.5M -129.09% | 29.4M +1,934.21% | 1.4M -63.95% | 4.0M +110.48% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 8.9M -56.99% | 20.7M +37.21% | 15.1M -26.33% | 20.4M -64.61% | |
Financials Ratio | |||||
Gross Margin | 80.51% +18.41% | 67.99% +194.55% | 23.08% N/A | N/A N/A | |
Operating Margin | -871.78% +1,136.25% | -70.52% -93.19% | -1,035.29% N/A | N/A N/A | |
Return on Assets | -5.08% -71.69% | -17.93% -79.24% | -86.40% +173.17% | -31.63% -24.78% | |
Return on Equity | -11.01% -84.07% | -69.11% -63.48% | -189.23% +350.98% | -41.96% -30.12% | |
Revenue Growth | -95.92% -119.07% | 502.92% N/A | N/A N/A | N/A N/A | |
Current Ratio | 1.95 +11.03% | 1.76 +15.04% | 1.53 -68.59% | 4.87 -17.56% | |
Cash Ratio | 0.27 -60.42% | 0.68 +391.23% | 0.14 -86.09% | 0.99 -25.83% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow